Cargando…

Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a highly effective treatment option for patients with relapsed/refractory large B-cell lymphoma. However, widespread use is deterred by the development of clinically significant acute inflammatory toxicities, including cytokine release synd...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jalota, Akansha, Hershberger, Courtney E., Patel, Manishkumar S., Mian, Agrima, Faruqi, Aiman, Khademi, Gholamreza, Rotroff, Daniel M., Hill, Brian T., Gupta, Neetu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468366/ https://www.ncbi.nlm.nih.gov/pubmed/36399526 http://dx.doi.org/10.1182/bloodadvances.2022007456

Ejemplares similares

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment
por: Panetti, Silvia, et al.
Publicado: (2022)

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells
por: Michelozzi, Ilaria M., et al.
Publicado: (2022)

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
por: Kim, Alexander B., et al.
Publicado: (2023)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden
por: Biondi, Marta, et al.
Publicado: (2023)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
por: Little, Jessica S., et al.
Publicado: (2023)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
por: Perriello, Vincenzo Maria, et al.
Publicado: (2022)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
por: McNerney, Kevin O., et al.
Publicado: (2023)

Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia
por: Rashidi, Armin, et al.
Publicado: (2021)

SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb
por: Rajagopal, Vaishnavi, et al.
Publicado: (2023)

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
por: Wobma, Holly, et al.
Publicado: (2023)

A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease
por: van Halteren, Astrid G. S., et al.
Publicado: (2023)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
por: Keller, Michael D., et al.
Publicado: (2020)

Catch those antibodies before they fall
por: Shaz, Beth H., et al.
Publicado: (2020)

Expanding the toolbox to combat a pandemic
por: Prockop, Susan E.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification
por: Martín Merinero, Hector, et al.
Publicado: (2021)

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
por: Nicolai, Leo, et al.
Publicado: (2022)

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n8rgn8rcjh4j0emvlrsu8nt926